Table 3.

List of clinical trials using tumor-specific antigens for CRC in their strategy.

Type of Therapy	Strategy	Combined Therapy	Number of Patients	Status	Trial Number
Vaccine	Personalized neoepitope yeast-based vaccine	–	16	Recruiting	NCT03552718
Peptide Vaccine	AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine	Montanide® ISA-51 VG	22	Completed	NCT01461148
Peptide vaccine	Personalized Synthetic Tumor-Associated Peptide Vaccine	Imiquimod, Pembrolizumab	60	Active	NCT02600949
Peptide Vaccine	mutant KRAS-targeted long peptide vaccine	Nivolumab and Ipilimumab	30	Active	NCT04117087
Adoptive Cell Therapy	TCR-engineered T cells against TGFBRII frameshift peptide	–	1	Terminated	NCT03431311
Adoptive Cell Therapy	CD8+T cells against personalized peptide antigens	Pembrolizumab	1	Active	NCT02757391
Adoptive Cell Therapy	neoantigen-targeting T cells	Nivolumab	148	Active	NCT03970382